Proliferation and Tumorigenesis of a Murine Sarcoma Cell Line in the Absence of DICER1

MicroRNAs are a class of short ∼22 nucleotide RNAs predicted to regulate nearly half of all protein coding genes, including many involved in basal cellular processes and organismal development. Although a global reduction in miRNAs is commonly observed in various human tumors, complete loss has not...

Full description

Saved in:
Bibliographic Details
Published inCancer cell Vol. 21; no. 6; pp. 848 - 855
Main Authors Ravi, Arvind, Gurtan, Allan M., Kumar, Madhu S., Bhutkar, Arjun, Chin, Christine, Lu, Victoria, Lees, Jacqueline A., Jacks, Tyler, Sharp, Phillip A.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 12.06.2012
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:MicroRNAs are a class of short ∼22 nucleotide RNAs predicted to regulate nearly half of all protein coding genes, including many involved in basal cellular processes and organismal development. Although a global reduction in miRNAs is commonly observed in various human tumors, complete loss has not been documented, suggesting an essential function for miRNAs in tumorigenesis. Here we present the finding that transformed or immortalized Dicer1 null somatic cells can be isolated readily in vitro, maintain the characteristics of DICER1-expressing controls and remain stably proliferative. Furthermore, Dicer1 null cells from a sarcoma cell line, though depleted of miRNAs, are competent for tumor formation. Hence, miRNA levels in cancer may be maintained in vivo by a complex stabilizing selection in the intratumoral environment. ► ID1 and ID3 together govern the maintenance of colon cancer-initiating cells ► ID1 and ID3 orchestrate their effect through the cell cycle inhibitor, p21 ► ID1 and ID3 expression reduces sensitivity to the chemotherapeutic drug, oxaliplatin
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work.
Present address: Cancer Research UK London Research Institute, 44 Lincoln’s Inn Fields, London WC2A 3PX, UK
ISSN:1535-6108
1878-3686
DOI:10.1016/j.ccr.2012.04.037